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ABSTRACT
In the United States, colorectal cancer (CRC) is the third most diagnosed cancer
and the second leading cause of cancer deaths. In 2015, approximately 143,000 new cases
will be diagnosed and 50,000 deaths are predicted. Liver metastasis is the major cause of
death. To understand the molecular and cellular mechanisms of liver metastasis, we used
an orthotopic mouse model of CRC liver metastasis that recapitulated all stages of tumor
growth and metastasis to perform whole genome microarray analysis to identify genetic
changes in the liver microenvironment in response to primary tumor growth in the cecum.
We identified lipocalin 2 (Lcn2) as the most highly expressed gene in pre-metastatic
liver. LCN2 is a 25 kD secreted glycoprotein that plays a key role in the innate immune
response. LCN2 has been associated with various types of cancers including thyroid,
cervical, breast, and renal. However, its role in the tumor microenvironment has not been
fully elucidated and there is conflicting data on its role in tumor growth and liver
metastasis of CRC. To determine the effect of elevated serum levels of LCN2 on liver
metastasis of CRC, Lcn2 was cloned into the pV1J plasmid and electroporated in vivo
into syngeneic mice while control mice were electroporated with pV1J empty vector.
MC38 CRC cells were then injected into the spleen of electroporated mice and the extent
of liver metastases was determined after three weeks. The results showed that mice
injected with Lcn2 expressing plasmid had elevated serum levels of LCN2 and showed a
significantly higher rate of liver metastasis as compared to mice electroporated with
empty vector.

The results suggest that elevated LCN2 expression in the
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microenvironment is sufficient to enhance liver metastasis of CRC, underscoring its
potential as a therapeutic target.
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CHAPTER 1
INTRODUCTION

1.1 COLORECTAL CANCER
Colorectal Cancer (CRC) is the third most common in both men and women,
accounting for approximately 650,000 deaths per year worldwide. In the United States, it
is the second leading cause of cancer-related fatalities (Society 2012). CRC is a term
used for cancer that starts in the colon or the rectum. These cancers can also be referred
to separately as colon cancer or rectal cancer, depending on where they start (Figure 1.1).

Figure 1.1 Diagram of the gastrointestinal system (GI). The colon and
rectum are parts of the digestive system, which is also called the GI system.
The large intestine is the portion of the digestive system. Food that cannot
be digested is passed on to the small intestine through the ascending,
transverse, descending, and sigmoid portions of the colon, and finally into
the rectum for excretion (Society 2014)
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Most colorectal cancers develop slowly over several years. Before a cancer
develops, a growth of tissue or tumor usually begins as a non-cancerous polyp on the
inner lining of the colon or rectum. A tumor is abnormal tissue and can be benign (not
cancer) or malignant (cancer) (Society 2014). A polyp is a benign, non-cancerous tumor.
Some polyps can progress into cancer but not all do. The chance of changing into a
cancer depends on the kind of polyp. There are a number of different types of polyps that
is encountered when dealing with colorectal cancer, but there are 2 main types that most
common. One type is adenomatous polyps also referred to as adenomas. They are polyps
that can change into cancer. Adenomas are considered as pre-cancerous condition. The
second type of polyps are hyperplastic and inflammatory polyps, which are not precancerous, but can become cancerous or might be an indication of a greater risk of
developing adenomas and cancer, particularly when these polyps are growing in the
ascending colon. Another kind of pre-cancerous condition is called dysplasia (Society
2012) wherein cells in an area in the lining of the colon or rectum appear abnormal when
viewed under a microscope. These cells can develop into cancer over time. Dysplasia is
usually observed in patients who have had diseases such as ulcerative colitis or Crohn's
disease for many years (Society 2014).
Adenomatous polyps begin in the cells of glandular structures lining the colon,
and are most likely to develop into cancer. Therefore, most colon cancers are
adenocarcinomas. Once the cancer forms and grows from a polyp, colon cancer cells can
eventually break through the intestinal wall of colon or rectum, spread into blood and
lymphatic vessels, and travel to the lymph nodes and distant organs, such as the liver.
Once these chain of events occur, this is referred to as metastasis (Society 2014).
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In the United States, approximately 143,000 new cases of CRC were predicted to
occur, and an estimated 51,000 fatalities are predicted in 2015 (Howlader N 2012). When
patients are diagnosed at a localized stage, the five year survival rate after resection is
approximately 90.8%; however, after metastasis has occurred, the five year survival rate
decreases significantly to 11.7% (Howlader N 2012).
Overall, the lifetime risk of developing colorectal cancer is about 1 in 20 (5%).
This risk is slightly lower in women than in men. A number of other factors such as
lifestyle related factors diet, weight, exercise, smoking, alcohol use, age, personal history
with colorectal polyps or colorectal cancer, personal history with inflammatory bowel
disease, and genetics can all affect a person's risk for developing colorectal cancer. The
death rate (the number of deaths per 100,000 people per year) from colorectal cancer has
been dropping in both men and women for more than 20 years (Society 2012; Society
2014). There are a number of likely reasons for this. One is that polyps are being found
by screening and removed before they can develop into cancers. Screening is also
allowing more colorectal cancers to be found earlier when the disease can still be curable.
In addition, treatment for colorectal cancer has improved over the last several years. As a
result, there are now more than 1 million survivors of colorectal cancer in the United
States (Howlader N 2012).
Many cases of colon cancer have no obvious symptoms. Most symptoms
indicating colon cancer are not specific, including abdominal pain and tenderness in the
lower abdomen, blood in the stool, diarrhea, constipation, or other changes in bowel
habits, narrow stools, and weight loss with no known reason (Society 2014). Even though
there is not an exact cause for colon cancer, there are a number possible ways it can be
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prevented. One of the most powerful ways to prevent CRC is through screening which
allows early detection and more likely curative intervention. There are a number of
screening tests that are used to detect polyps and CRC; some of these tests include the
Guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT),
where stool samples are checked for blood and cells that might indicate the presence of a
polyp or cancer. Another test that may be used is the stool DNA test where a stool sample
is checked for certain abnormal sections of DNA (genetic material) from cancer or polyp
cells (Cunningham, Atkin et al. 2010).
Sigmoidoscopy is a method where a flexible, lighted tube is inserted into the
rectum and lower colon to check for polyps and cancer. One of the most common tests
performed today is a colonoscopy wherein a longer, flexible tube is used to examine the
entire colon and rectum. Other tests that are less commonly used include the double
contrast barium enema. This is an x-ray test of the colon and rectum and CT
colonography (virtual colonoscopy) is a type of CT scan of the colon and rectum. The
most common screening examinations to detect CRC and polyps are qFOBT, FIT, and
stool DNA test (Smith 2012)
In addition to the methods above, CT or MRI scans of the abdomen, pelvic area,
chest, or brain may be used to stage the cancer to discern if the cancer has spread .The
staging is used to describe the extent of penetration of the cancer (Network 2013).
Specifically in colon cancer, it is based on the depth by which the cancer has invaded into
the intestine wall, whether or not it has reached nearby structures, and whether or not it
has spread to the lymph nodes or distant organs. In the clinic, the stage of a cancer is
viewed as the most important factor in determining the prognosis and treatments of
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patients. Usually, there are two types of staging for colon cancer: clinical and pathologic
stages, based on the physical exam, biopsy, and other tests. The pathologic stage is most
often used, because it includes the results from surgery, and is more accurate
(Cunningham, Atkin et al. 2010). The typical stages of CRC progression are described in
Figure 1.2.

Figure 1.2. Progression of polyp development into cancer on the lining of the intestinal
wall, Stage 0: Very early cancer on the innermost layer of the intestine; Stage I:
Cancer is in the inner layers of the colon; Stage II: Cancer has spread through the
muscle wall; Stage III: Cancer has spread to the lymph nodes; Stage IV: Cancer has
spread to other organs outside the colon (John’s Hopkins University)

Treatment of colon cancer depend on many factors, especially the stage of the
cancer during patient diagnosis. Standard treatments include surgery to remove the
primary tumor lesion that may be followed by chemotherapy to kill cancer cells, and
radiation therapy to destroy cancerous tissue. For CRC at stages 0, I, II, and III, tumor
resection and 6-8 months of adjuvant chemotherapy is a typical therapeutic plan,
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sometimes combined with radiation therapy. For patients with stage IV disease with
distant metastasis, treatments directed at metastatic lesion also need to be administered.
However, the efficacy is typically very limited (Society 2012).
Among the complications of colon cancer, metastasis is undoubtedly the leading
cause of death. Although metastasis occurs by the successful completion of multiple
complicated steps by the metastatic cancer cells, these often occur without symptoms.
Furthermore, early symptoms are not specific and when metastases occur, patients have
already missed the opportunity to be treated successfully through surgery or irradiation
(Chambers, Groom et al. 2002). The liver is one of the most common sites of metastatic
spread of colon cancer (Hanahan and Weinberg 2011). At the time of diagnosis,
approximately 20-25% of patients with colon cancer already present with liver
metastasis. However, autopsy results revealed that up to 70% of colon cancer patients had
liver metastases. Given these colorectal cancer statistics, it is effortless to conclude that
liver metastasis is the major and direct cause of diminished survival in colon cancer
patients (Schima 2005) and understanding its progression can lead to better diagnosis and
treatment.
1.2 CANCER METASTASIS
A genetic model for describing the progression of CRC is the Vogelstein model (the
Vogelgram), which was introduced 1990. In this model, the transformation from a
normal to neoplastic cell begins with a mutation in the adenomatous polyposis coli (APC)
tumor suppressor gene, which is a key protein in the Wnt signaling pathway (Nusse and
Varmus 1992). This mutation is similar to that found in the hereditary variant of CRC
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called familial adenomatous polyposis or FAP. The wild type APC protein forms a
complex with axin and GSK-3β in the absence of Wnt signaling (Roelink, Wagenaar et
al. 1992). The protein complex promotes the phosphorylation and subsequent
proteasomal degradation of β-catenin, which is an intracellular signaling molecule. When
APC is mutated, β-catenin escapes degradation and enters the nucleus and binds to
TCF/LEF transcription factors, which activates transcription of genes such as MYC (cMyc, a proto-oncogene) and possibly PTGS2 (COX-2) (Nusse and Varmus 1992; Gordon
and Nusse 2006).
Beyond the defects in the Wnt signaling pathway, other mutations must occur for the
cell to become cancerous. The p53 protein, a product of the TP53 gene, normally
monitors cell division and targets cells for apoptosis cells if the Wnt pathway is defective.
Eventually, mutated cells acquire a mutation in the TP53 gene and transforms the tissue
from a benign epithelial tumor into an invasive epithelial cell cancer. Sometimes the gene
encoding p53 is not mutated, but another protective protein named BAX is mutated
instead (Isobe, Emanuel et al. 1986; Cho, Gorina et al. 1994).
Metastasis is a multi-step process that is silent and undetectable in the early stages.
Tumor invasion is the initial event in the metastatic cascade and is primarily mediated by
regulated interaction of tumor cells with the surrounding extracellular matrix (ECM).
This step of metastasis requires tumor cells to attach, proteolyze and migrate through the
basement membrane and enter into the circulation (Fidler 2003). Once tumor cells detach
from the primary tumor mass, they enter into the circulatory or lymphatic system. This
process is called intravasation. Once in circulation, they no longer get the survival signals
they normally receive from cell-cell and cell-ECM interactions (Kaplan, Rafii et al.
7

2006). Tumor cells with metastatic potential acquire several mechanisms to evade this
process and acquire resistance to immune cells that are trying to kill them. This resistance
not only provides them with increased survival but also facilitates reattachment and
colonization at secondary sites in a process called extravasation (Gupta, Minn et al. 2005;
Kaplan, Rafii et al. 2006).
The last and final stage of the metastatic cascade is the colonization of the
secondary site. Metastasis is not a random process. After performing a large number of
autopsies, Stephen Paget proposed the ‘seed and soil’ hypothesis wherein he proposed
that certain disseminated tumor cells (seed) preferentially colonize to specific organs
whose microenvironment (soil) is compatible for their growth and proliferation (Paget
1989). For example, breast cancers frequently metastasize to lungs, liver, bone, and brain
whereas prostate cancers metastasize to the bone. This hypothesis was refuted by James
Ewing who proposed that distant metastasis at specific sites is primarily determined by
the vasculature at the primary site (Ewing 1928). Recent advances and emerging data
strongly support Paget’s hypothesis and stresses the concept of a viable tumor
microenvironment or ‘pre-metastatic niche’ where metastasizing tumors cells can attach
and engraft at distant sites (Kaplan, Rafii et al. 2006).
1.3 TUMOR MICROENVIRONMENT AND ROLE OF LCN2 IN CANCER
The progression of CRC not only depends on genetic events. Changes in tissue
microenvironment and expression of growth factors and other signaling factors are also
of major importance (Woodhouse, Chuaqui et al. 1997; Perl, Wilgenbus et al. 1998). A
tumor is not only made up of dividing, mutated epithelial cells. It also consists of
vascular, inflammatory, and other activated stromal cell. Interactions between tumor cells
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and cells within the stroma through soluble molecular factors have a profound impact on
cell proliferation, movement, and differentiation (Egeblad and Werb 2002).
The tumor microenvironment, which is also the tumor-associated stroma is thus
the cellular milieu in which the tumor exists, and includes the surrounding blood vessels,
non-neoplastic cells such as infiltrating immune cells, fibroblasts, and endothelial cells,
adipocytes, various bone marrow-derived cells such as mesenchymal stem cells, as well
as macrophages and other immune cells, and the extracellular matrix (ECM) (Hanahan
and Coussens 2012). It is considered as an important hallmark of cancer, which
contributes to the cancer development and progression. They secrete growth factors,
chemokines, cytokines, and reactive oxygen species. It was previously postulated that
cellular components were only recruited by molecular signals from cancer cells.
Currently, it has been shown that these cells are influenced by cancer cells and work
closely with them to support tumor progression by not only enhancing the growth of the
primary tumor but also directing its metastatic dissemination to distant organs (Matrisian,
Cunha et al. 2001). The immune cells in the tumor microenvironment represents the
major inflammatory component of the stroma of many tumors (breast, prostate, glioma,
lymphoma, bladder, lung, cervical and melanoma) and are able to affect different aspects
of the neoplastic tissue (Matrisian, Cunha et al. 2001). For example, tumor-infiltrating
immune cells can promote invasion, metastatic dissemination and seeding of cancer cells
via their presence at the invading margins of the tumor; tumor associated fibroblasts can
also modulate tumor cell invasion and metastasis; while endothelial cells have been
shown to regulate angiogenesis (Ahmed and Bicknell 2009).
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These findings provide examples of the bidirectional interactions that occur
between tumor cells and nearby stroma and contribute important factors to the biology of
the tumor. Previous works focused on the tumor as a single cancer cell type but current
findings suggest that the tumor should be treated as an organ in which there is a
heterogeneous collection of cancer cells that collaborate with an equally heterogeneous
collection of tumor stromal cells that contributes to such function as: initiation,
proliferation and invasion (Mantovani 2010). Carcinoma cells stimulate the formation of
an inflamed stroma, and the latter reciprocates by supplying various growth factors and
cytokines thereby enhancing the malignant traits of the carcinoma cells. This depends on
back-and-forth reciprocal heterotypic signaling between cancer cells and supporting
stromal cells during the stepwise progressing of the tumor which establishes a potentially
self-amplifying positive feedback loop (Xu, Rajagopal et al. 2010).
According to Weinberg et al, the transition from normal to benign to metastatic is
not just driven by events inside the tumor cell itself but also by events around it.
Throughout this intricate process, the tumor stroma is viewed as an integral part in the
progression of multistep tumorigenesis. During the transformation of normal tissue into
malignant, both neoplastic cells and stromal cells around then change and this
histopathological progression must reflect underlying changes in heterotypic signaling
between tumor parenchyma and stroma (Hanahan and Weinberg 2011).
Therefore, this reciprocal interaction between cancer and host environment appear
to be a dynamic duo that assist each other by heterotypic signaling during tumor
progression in which leads to metastasis. When analyzing the communications between
the tumor and host microenvironment it is imperative to fully understand the mechanisms
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and infrastructure because this will help us conquer cancer metastasis by unlocking the
underlying mystery of the cancer cells and the multiple networks and support them in
hopes to destroy them (Cheng, Chytil et al. 2008).
In recent years, there have been a number of studies with the goal and intent to
reverse the tumor-enhancing effects of the microenvironment and recreate a repressive
host tumor interaction while metastasis is in progress. While, there are a number of
therapeutic agents that target certain stromal cells to block the host-tumor interactions
like VEGFA and VEGFR inhibitors, EGFR and CSF1R antagonists, chemokine
inhibitors, including CXR4 antagonist, TNF-α inhibitors, and protease inhibitors. Their
effects have shown some positive signs but over time the emergence of resistance puts a
halt to all progress. In order to figure out the complex problem of metastasis further
understanding of host-tumor interaction is vital (Hiratsuka, Nakamura et al. 2002;
Shojaei, Wu et al. 2007).
1.4 PREVIOUS STUDY REVEALS LCN2 WAS MOST HIGHLY EXPRESSED GENE
IN LIVER MICROENVIRONMENT.
In previous studies by Zhang et al., the CT26 mouse colon adenocarcinoma cell
line was used to develop a mouse model for spontaneous metastasis to the liver in
syngeneic Balb/c mice. This metastatic model required the injection of CT26 cells into
the flank of Balb/c mice; tumors were removed and a single cell suspension was
obtained. These CT26-F1 cells were then injected into the cecum of the Balb/c mice,
which increased the incidence of metastasis to the liver from 8 to 50%. However, with
three sequential passages of these cells through the liver, the highly metastatic CT26-FL3
cell line was obtained. The CT26-FL3 cell line was ten times more metastatic than the
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CT26 cells, 90% versus 8% frequency of metastasis, respectively (Zhang, Davis et al.
2013).
The CT26-FL3 cell line was implanted into the cecum of Balb/c mice. Liver
samples from tumor bearing mice were analyzed prior to metastasis by microarray
analyses to identify genetic changes in the liver in the response to tumor growth in the
cecum. As a control, liver samples from mice injected with PBS were also analyzed. For
this study an Agilent mouse whole genome microarray kit was used to identify genes that
were differentially expressed in the liver microenvironment in response to primary tumor
growth in the cecum. The most highly expressed gene, lipocalin 2 (LCN2) (Iannetti,
Pacifico et al. 2008) was found to be upregulated in the pre-metastatic liver prior to the
presence of metastasis. Immunoblot analysis further showed that tumor-bearing mice
displayed increasing levels of LCN2 in the serum during tumor progression to metastasis.
Elevated levels of lipocalin protein was not seen in mice that had undergone sham
surgery and injected with PBS (Zhang, Davis et al. 2013).
1.5 THE SIGNIFICANCE AND ROLE OF LCN2 IN CANCER
Lipocalin 2 (LCN2) is a 25 kD secreted glycoprotein that plays a key role in the
body’s innate immune response (Leng, Ding et al. 2009). LCN2 binds to small lipophilic
molecules such as retinols, prostaglandins, pheromones, catecholates, and matrix
metalloproteinase 9 (MMP9). Lcn2 is known as neutrophil gelatinase associated lipocalin
and as mouse oncogene 24p3. There are about 20 types of lipocalin lipoproteins, and all
share an eight strand anti-parallel β-barrel around a central binding pocket (Berger,
Cheung et al. 2010). Lipocalin 2 is an antimicrobial product similar to β-defensin and

12

binds to microbial siderophores that are chatecholate-like and sent from microbial cells to
scavenge iron from the environment.
LCN2 interacts with the 24p3 receptor, also known as megalin, with or without a
bound moiety and transports the moiety into the cell. In an infected state, neutrophils are
the first leukocytes to an infection where they can secret Lcn2 to scavenge iron in order
to reduce the metabolically essential minerals for infectious bacteria (Srinivasan, Aitken
et al. 2012). LCN2 was first discovered in neutrophils and is highly expressed in tissues
that have high exposure to bacteria such as esophagus, bone, lung, bone marrow,
stomach, and salivary glands (Flower 1996). LCN2 not only binds bacteria siderophores,
but it can also bind mammalian chatechols and transport iron throughout the body, as
seen mostly in the kidney.
LCN2 has been shown to have altered expression in multiple cancers, including
colorectal, breast, renal, cervical, and thyroid during their progression (Bao, Clifton et al.
2010). However, there are conflicting data over the effects of LCN2 both on the primary
tumor and in metastasis. According to Iannetti et al, LCN2 expression was found to have
an inverse correlation with metastatic potential in a human colon cancer cell line
(Iannetti, Pacifico et al. 2008). In breast cancer one report showed that inhibition of
LCN2 did not block metastasis, while others showed that inhibition of LCN2 blocked
metastasis (Iannetti, Pacifico et al. 2008) (Rius, Guma et al. 2008). A previous study
conducted by Iannetti et al, on thyroid tumors gave some understanding as to how LCN2
could possibly have multiple roles in tumorigenesis, carcinogenesis, and metastasis
(Seandel, Butler et al. 2008).
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While lipocalin-2 has been implicated in various types of cancers including thyroid,
cervical, breast, and renal (Flower 1996; Lee, Lee et al. 2006; Iannetti, Pacifico et al.
2008; Seandel, Butler et al. 2008; Bao, Clifton et al. 2010), its has not been explored in
the microenvironment when levels of LCN2 have been elevated. Little is also known
about its role in tumor growth and liver metastasis. Therefore, the data gained from this
project could identify novel roles of LCN2 in the microenvironment that might promote
metastasis. These findings might also clarify the contrasting roles of Lcn2 in colorectal
cancer progression.
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CHAPTER 2
THE EFFECT OF MICROENVIRONMENT SECRETION OF LCN2 ON LIVER
METASTASIS OF COLORECTAL CANCER CELLS

2.1 GOAL AND OBJECTIVE OF CURRENT STUDY
CRC metastasis is a multistep process that is fatal and is not well understood
because it can develop undetected until it is too late. More research must be done on the
biological and molecular hallmarks that direct the early stages of metastasis, a stage that
if diagnosed can provide the best opportunity for therapy to block its progression.
Metastasis takes place through multiple steps mediated by complex interactions between
the primary tumor and the target organ to promote malignant growth. It is important to
identify the genetic and molecular changes taking place in the target organ in response to
the growth of cancer cells in the primary tumor. Understanding the mechanisms they
direct will ultimately aid in significantly lessening the impact of colorectal cancer on the
patient.
The overall goal is to determine the role of Lcn2 in promoting the early stages of
colon cancer metastasis to the liver. The research question being examined is: Does
increased circulating levels of LCN2 in mice promote the metastasis of CRC to the liver?
We hypothesize that elevated the serum levels of LCN2 is sufficient to enhance tumor
growth and liver metastasis of MC38 colon adenocarcinoma cells. Because LCN2 can be
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secreted by hematopoietic cells in the tumor microenvironment that are involved in CRC
metastasis, the results from this study will complement previous research that was
conducted by Zhang et al. The mouse model developed by Zhang et al. will be used in
combination with intramuscular in vivo electroporation to increase serum levels of LCN2
to examine the effect on liver metastasis of CRC. In order to complete this task, three
aims were proposed:
Aim One: To construct a plasmid that will overexpress Lcn2 that will be injected into
C57Bl/6 mice.
Aim Two: To inject C57Bl/6 mice intramuscularly with 50 μg of purified endotoxin free
LCN2 overexpressing plasmid, followed by in vivo electroporation to increase serum
levels in the mice. We will determine the kinetics of Lcn2 expression after
electroporation by analysis of serum levels by ELISA.
Aim Three: To examine the rate of metastasis to the liver under conditions of
physiological or elevated LCN2 levels by splenic implantation of MC38 mouse colon
tumor cells after in vivo electroporation of Lcn2 over-expressing plasmids. We will
measure the weights of the spleens and livers after implantation (four weeks) to assess the
effect of LCN2 on primary tumor growth and liver metastasis of CRC cells.
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2.2 MATERIALS AND METHODS
Construction of the pV1J-LCN2 plasmid
The pV1J-LCN2 plasmid was constructed from pCMV6-LCN2 plasmid and pV1J
plasmid. The Lcn2 gene in the pCMV6-LCN2 plasmid was PCR amplified with forward
primer 5’ TCGACTGGATCCGGTACCGAGGAGATCTGC3’ and reverse primer
5’GCCGAATTCGGCCGTTTAAACCTTATCGTC 3’ that contained the restriction sites
for KpnI and EcoRI at the 5’ and 3’, respectively. The PCR product was electrophoresed
on a 1% agarose gel. The 752 bp fragment containing Lcn2 was excised from the gel and
was purified by PCR Clean-up System from Promega. The purified LCN2 fragment was
cloned into the pGEMT-Easy vector. The ligated fragments were transformed DH5α
competent cells purchased from Life Technologies (Carlsbad, CA). The pGEMT-Easy
vector and LCN2 fragment were incubated on ice for 20 minutes, followed by heat shock
at 42° C for 2 minutes, and then the mixture was placed on ice for 2 additional minutes.
Then 950 μL of LB media (no antibiotics) was added the mixture and it was allowed to
incubate on a shaker for one hour. 200 μL of the transformation mix was placed on LB
plates containing Ampicillin (100 ug/mL), X-Gal, and IPTG. The plates were incubated
overnight at 37°C. The following day the screening was conducted by picking white
colonies from the plate. The colonies were then grown in liquid LB media with
Ampicillin (100 ug/mL). Plasmids were purified using Qiagen plasmid mini-prep kit
following manufacturer’s instructions. A restriction enzyme digestion was then
performed to determine the ligation of LCN2 into the pGEMT-Easy vector. A sequential
digestion was performed with EcoR1 and Kpn1, to release the 752bp fragment of LCN2.
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Plasmids containing the Lcn2 fragment were sequenced by GeneWiz Inc. (Research
Triangle Park, NC).
Upon verification of the LCN2 sequence, the pGEMT-Easy-LCN2 plasmid was
digested with Kpn1 and EcoR1. The same restriction enzymes were used to excise the
pV1J expression plasmid. The pV1J and LCN2 fragments were purified, ligated and
transformed into DH5α competent cells and plated in LB plated containing Kanamycin
(50 ug/mL), X-Gal and IPTG. Plasmids were purified from transformed cells and verified
by digestion with KpnI and EcoRI as previously described.
Purification of Endotoxin Free pV1J-Lcn2 and pV1J plasmid
Bacteria transformed with pV1J and pV1J-Lcn2 DNA were grown overnight in
2.5 liters LB containing Kanamycin. Endotoxin free plasmid preparations for in vivo
electroporation were purified using Qiagen Plasmid Plus Giga Kit following
manufacturer’s instructions. The concentration of pV1J and pV1J-Lcn2 DNA were
measured by a spectrophotometer.
Cell Culture
The C57BL/6-derived mouse colon carcinoma cell line MC38 was purchased
from American Type Culture Collection (ATCC), and cultivated in Dulbecco’s
Modification of Eagle’s Medium (DMEM) with 4.5 g/L glucose (Mediatech, Manassas,
VA) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA) and 1% Penicillin/Streptomycin (Pen/Strep, Mediatech, Manassas,
VA) at 37°C and 5% CO2 in a humidified atmosphere. pV1J or pV1J-Lcn2 was
transiently transfected using Lipofectamine 2000 (Invitrogen, Grand Island, NY)
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following manufacturer’s instructions.
Western blotting
Expression of LCN2 in total cellular protein extract. Cells that were 80-90%
confluent and had been transiently transfected with pV1J or pV1J-Lcn2 plasmids for 72
hours were washed with 5 mL of HBSS and was aspirated. 2 mL of Trypsin was added
and the cells were placed in the 37° C incubator for 5 minutes. After 5 minutes DMEM
was added to stop the reaction of the Trypsin. Next the cells were placed in a 15 mL
Eppendorf tube and centrifuged at 2000 rpm for 5 minutes. The supernatant above the
pellet was aspirated and the cells were re-suspended in 5 mL of PBS and washed. The
wash and centrifugation was repeated. After the last wash, the supernatant was aspirated
and the pellet was re-suspended in 1 mL of PBS and centrifuged at 2000 rpm and 5
minutes. The cells in the final pellet were re-suspended in 200 μL of Mammalian Protein
Extraction Reagent and 1 μL of 500X Protease Inhibitor was added to each sample. The
samples were vortexed and placed on ice for 10 minutes and then centrifuged at 11,000
rpm for 1 hour at 4°C. Protein samples were quantitated by the Bradford assay using an
Epoch plate reader (Biotek Instruments, Inc Winooski, VT).
Equal protein amounts were subjected to electrophoresis on a 10% SDS-PAGE
gel, followed by electrophoretic transfer to nitrocellulose filters.

After successful

membrane transfer, 5% milk in PBST was added to the membrane, and incubated at room
temperature for 1hour. The blot was then washed 3 times for 10 minutes with PBST. A
goat monoclonal antibody against the Lcn2 protein was used as a probe: (Abcam,
Cambridge, MA). The blot was incubated with primary antibody (1:1000) overnight at
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4°C, washed three times with PBS/0.01% Triton X-100, followed by HRP-conjugated
secondary antibody (Bio-Rad, Hercules, CA)(1:5000) for 1 hour at room temperature.
The blots were visualized using an ECL enhanced chemiluminescence kit (GE
Healthcare, Piscataway, NJ). As internal controls for equal protein loading, blots were
stripped and probed with antibodies against albumin (Santa Cruz Biotechnology, Santa
Cruz, CA).
Expression of LCN2 in protein in media. Media from cell culture plates
containing cells that were 80-90% confluent and had been transiently transfected with
pV1J or pV1J-Lcn2 plasmids for 72 hours, was collected in a 15 mL Eppendorf tube. The
cell media was then concentrated using Centriprep Centrifugal Filters from Millipore
(Merck KGaA of Darmstadt, Germany). After the media was concentrated it was diluted
1:10 with molecular grade water. Then 5 μL of diluted sample was mixed with 10 μL of
molecular grade water and 3 μL of 6X for a total of 18 μL. Samples were boiled at 100
°C for 10 minutes. SDS-PAGE electrophoresis and transfer to nitrocellulose was
performed as described above. Then antibody against the LCN2 protein was used as a
probe: (from Abcam, Cambridge, MA). The blot was incubated with primary antibody
(1:1000) overnight at 4°C, washed three times with PBS/0.01% Triton X-100, followed
by HRP-conjugated secondary antibody (Bio-Rad, Hercules, CA)(1:5000) for 1 hour at
room temperature. The blots were visualized using an ECL enhanced chemiluminescence
kit (GE Healthcare, Piscataway, NJ). As internal controls for equal protein loading, blots
were probed with antibodies against albumin (Santa Cruz Biotechnology, Santa Cruz,
CA).
Splenic injection of MC38 mouse colon cancer cells
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Sub-confluent MC38 cells were harvested and washed in phosphate buffered
saline (PBS) just prior to implantation. Eight-week-old male C57BL/6 mice were
anesthetized by inhalation of 2% isoflurane in oxygen and placed in supine position. A
midline incision was made to exteriorize the spleen. Using a 33-gauge micro-injector
(Hamilton Company, Reno, NV), 2×105 cells in 10-15 uL were injected into the spleen.
The injection site was sealed with a tissue adhesive (3M, St. Paul, MN) and sterilized
with 70% alcohol to kill cancer cells that may have leaked out. The spleen was placed
back into the cavity and the abdominal wall and skin closed with 6-0 polyglycolic acid
absorbable sutures (CP Medical, Portland, OR). This process was conducted with mice
twenty-four hours after in vivo electroporated of pV1J and pV1J-Lcn2 plasmids.
Measurement of serum levels of pV1J-Lcn2 after in vivo electroporation
Sera from mice electroporated with pV1J and pV1J-Lcn2 plasmids were collected
at the indicated time points after electroporation and analyzed by immunoblotting. Using
antibodies against the LCN2 protein was used as a probe: (from Abcam, Cambridge,
MA) as described above. As internal controls for equal protein loading, blots were
stripped and probed with antibodies against albumin (Santa Cruz Biotechnology, Santa
Cruz, CA).
Alternatively, LCN2 levels in sera were analyzed by ELISA using Lipocalin2/NGAL Mouse ELISA kit from Abcam following manufacturer’s instructions. Sera
from mice was allowed to clot for 2 hours at room temperature then centrifuged at 2000
rpm for 20 minutes. Standard solutions were prepared in a concentration range of 156 to
5000 pg/mL. Standards, their duplicates, and properly diluted sera samples were
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aliquoted at 100 uL per well in a 96-well plate. The plate was sealed and incubated at
37°C for 90 minutes. The cover was removed and the plate contents discarded and
blotted onto paper towels. 100L of biotinylated anti-mouse LCN2 antibody working
solution was then added into each well and incubated at 37°C for 60 minutes. The plate
contents were discarded and the plate was washed 3 times with create 0.01 M PBS
washing buffer, each time allowing the buffer to stay in wells for 1 minute. Buffer was
discarded and the plate blotted. 100 uL of ABC working solution was added into each
well and incubated at 37°C for 30 minutes. The plate content was discarded and the plate
was washed 5 times with washing buffer, each time allowing the buffer to stay in wells
for 1 to 2 minutes. Buffer was discarded and plate blotted. 90 uL of TMB color
developing agent was added into each well and incubated at 37°C for 20 to 25 minutes.
Next, 100 uL of TMB stop solution was added into each well which resulted in a color
change to yellow immediately. OD absorbance was read at 450 nm using BioTek’s Epoch
Micro-Volume Spectrophotometer System and concentration of standard solution in
pg/mL was graphed against optical density readings of standards.
In vivo Electroporation
Prior to surgery, the mice were anesthetized by inhalation of 5% isoflurane in
oxygen delivered at 1 L/minute. Anesthesia was maintained in the induction chamber at
2.5% in oxygen. The mice were placed on the sterile operating table with a nose cone
delivering the same concentration of isoflurane in oxygen. The thigh hair was shaved and
a small incision was made in the skin at the bottom of the thigh just above the knee. This
slit is expanded by further careful handling of scissors to uncover fatty tissue which was
removed to expose the quadricep muscle. 50 μg of pV1J or pV1J-Lcn2 plasmid in PBS
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were injected in a final volume of 15 or 30 μL into the quadriceps, while holding the
syringe vertically and perpendicular to the muscle and quickly pulling out afterwards.
The BTX ECM 830 ElectroSquare Porator was used to apply three pulses of electricity at
100V for 50 milliseconds to allow the muscle to take in the plasmid and consequently
express LCN2 protein to be secreted into the bloodstream. Animal procedures have been
approved by the USC Institutional Animal Care and Use Committee.
Assessment of tumor burden and metastasis
Tumor burden and metastasis was analyzed after mice were humanely sacrificed.
Spleens and livers were weighed to determine the growth of primary tumor and the rate
of metastasis to the liver.
2.3 RESULTS AND CONCLUSION
In order to assess the effects of elevated circulating levels of LCN2 on liver
metastasis of colorectal cancer, a plasmid needed to be constructed to manipulate LCN2
levels in vivo.

23

Figure 2.1. Map of plasmid pV1J-Lcn2. Lcn2 is constitutively expressed by the CMV
Promoter and the plasmid confers Kanamycin resistance to transfected cells.

The pV1J backbone (Figure 2.1) was chosen because it has been optimized to
express encoded genes when delivered intramuscularly by in vivo electroporation and it
has been shown to be an efficient plasmid to increase circulating levels of the gene of
interest. The plasmid map of pV1J- Lcn2 is shown in Figure 2.1.
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Figure 2.2. Examination of Intracellular protein from MC38 cells that were either
untransfected, transfected with pV1J-Lcn2, or pV1J vector only. The cells were
transiently transfected for 72 hours, harvested, and total protein extracts were
obtained. The proteins were separated on a 0.8% SDS-PAGE and analyzed by
immunoblotting.

After transiently transfecting MC38 cells for 72 hours with pV1J- Lcn2 plasmid,
intracellular protein was analyzed to determine the uptake of the plasmid into the cells
and expression of LCN2. If the cells successfully uptake the plasmid and express it, the
muscle cells would also be able to uptake the plasmid and spread it systemically
throughout the mouse for expression. Immunoblot analysis of transiently transfected cells
showed that the plasmid was up-taken and expressed LCN2 (Figure 2.2). The figure
shows that the LCN2 levels in cells transfected with pV1J- Lcn2 is expressed higher than
levels in cells transfected with the pV1J empty vector or untransfected cells.
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Figure 2.3 Immunoblot analysis of extracellular LCN2 in media from MC38 cells. Cells
were transiently transfected for 72 hours and harvested. Cells were either untreated,
transiently transfected with pV1J vector only or pV1J-Lcn2 plasmids. The protein
extracts were normalized against Β-actin protein.

Since LCN2 is typically secreted, the extracellular protein levels in the cell cuture
media were also analyzed. Immunoblot analysis of the cell culture media from transiently
transfected cells showed a higher level of LCN2 protein was present in the media from
cells transfected with pV1J- Lcn2 as compared cells transfected with the empty vector or
untransfected cells (Figure 2.3). These data indicate that LCN2 can be expressed from the
pV1J vector and is secreted and therefore, the plasmid can potentially be used to increase
its circulating levels in the blood.
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Figure 2.4: Fold change of extracellular protein levels between non-transfected MC38
cells and cells transfected with pV1J vector or pV1J-Lcn2 plasmid. Cells were
transiently transfected for 72 hours and harvested. Protein was quantitated by ELISA
that probed with an antibody against LCN2.

The media collected from the cells was further analyzed by ELISA, which is a
common laboratory technique which is used to measure the concentration of an analyte
(usually antibodies or antigens) in solution. The results showed that cells transfected with
pV1J- Lcn2 secreted 2.5-fold higher LCN2 than cells transfected with the pV1J empty
vector and untransfected cells (Figure 2.4). This is expected since LCN2 is being
overexpressed in the cells.
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Figure 2.5 Measurement of concentration of LCN2 in sera at various time points after in
vivo electroporation with pV1J-Lcn2 or pV1J. Sera were quantitated by ELISA that
probed with an antibody against LCN2.

To determine if the plasmids were capable of increasing circulating levels in sera,
mice were electroporated with pV1J or pV1J- Lcn2 plasmids. Blood was withdrawn
prior (Pre-bleed) to electroporation and then every week for 4 weeks to determine how
long the LCN2 levels stay elevated after electroporation. The concentration of LCN2 in
blood sera was analyzed by ELISA. Figure 2.5 shows that electroporation of pV1J- Lcn2
resulted in a three-fold increase in serum levels of LCN2. Elevated levels were
maintained for 4 weeks after which they dropped to the same levels as mice injected with
pV1J empty vector. Electroporation of pV1J empty vector caused a slight increase in
LCN2 over the pre-bleed levels of approximately 0.1-fold. Therefore, plasmid pV1JLcn2 is capable of increasing circulating levels of LCN2 after intramuscular in vivo
electroporation into recipient mice.

28

Figure 2.6 Comparison of LCN2 serum levels before and after electroporation with
pV1J or pV1J-Lcn2. Samples were examined at various time points. The proteins were
separated on a 0.8% SDS-PAGE and was normalized against albumin protein.

We further determined LCN2 levels in sera by western blotting. Sera from prebleed, and weeks 1, 3, and 4 after electroporation were analyzed. Consistent with the
results from ELISA, LCN2 levels in sera from mice electroporated with pV1J empty
vector was fairly constant throughout the experiment while sera from mice electroporated
with the pV1J- Lcn2 plasmid showed an increased LCN2 levels in the gene throughout
the progression of the experiment (Figure 2.6). The western blot was normalized by
albumin.
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Figure 2.7: Comparison of LCN2 serum levels in LCN2 knockout mouse, wildtype
mice, and mice that were in vivo electroporated with pV1J-Lcn2 or pV1J plasmid. The
proteins were normalized against albumin protein.

The expression of LCN2 was analyzed in Lcn2-/- knockout mice, wild tyoe mice,
and mice electroporated with pV1J-Lcn2 mouse and pV1J empty vector. The knockout
mouse is shows a faint band of similar size to LCN2 , in which it should not, but from
some previous studies the immunoglobulin G (IgG) heavy chains may be being crossreacting (Figure 2.7). PCR analysis confirms that the mouse is an Lcn2 knockout. The
wild type mouse and the mouse electroporated with the pV1J plasmid mouse expression
express comparable levels of LCN2, while the mouse electroporated with pV1J-Lcn2
overexpression expression is expressing approximately three-fold higher LCN2 levels
than the previous two groups (Figure 2.7). These samples were normalized for equal
loading using albumin.
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Figure 2.8: Assessment of rate of liver metastasis in mice injected with 50 μg of pV1JLcn2 or pV1J plasmids. The weights of the spleen and liver were recorded to determine
the rate of metastasis.

To determine the effect of elevated circulating levels on tumor growth or liver
metastasis, 2x105 MC38 cells were implanted into the spleen of eight-week-old C57BL/6
mice one day after in vivo electroporation of pV1J- Lcn2 plasmid or pV1J empty vector
Sera were harvested weekly after electroporation. Three weeks after spleen injection, the
mice were humanely sacrificed and spleen and livers were harvested and weighed. Two
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sets of experiments were conducted with N=20 for both experiments. 50 μg pV1J- Lcn2
or pV1J was injected into each mouse. Figure 2.8 shows the size of the primary tumor in
the spleen and metastatic lesions in the liver for each mouse. Examination of these photos
suggest that primary tumor size in the spleen is not affected by elevated LCN2 circulating
levels; however the size and number of liver lesions is much higher in mice electroprated
with pV1J- Lcn2. The spleens (primary tumor) and livers (metastasis) were weighed.
The results shown in Figure 2.9 show that in both sets of experiments, there was no
significant difference in the weights of the primary tumor in the spleen. On the other
hand, the mice that were injected with pV1J- Lcn2 had larger livers and more metastases
as compared to mice injected with the empty vector. p-values for these differences in
liver weight in both experiments were 0.029 and 0.0066, respectively. Collectively, these
data suggest that elevated LCN2 levels in the sera can promote liver metastasis of MC38
colon cancer cells whose LCN2 expression is not altered.
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Figure 2.9: Spleen and liver weights were analyzed four weeks after splenic injections of
MC38 cells and in vivo electroporation of pV1J-Lcn2 or pV1J plasmids.

2.4 DISCUSSION
It is important to study potential biomarkers and their roles when examining the
key transition of colon cancer metastasis to the liver. If it is confirmed that the
upregulated presence of a target protein or other molecule coincides with the progression
to the exceedingly lethal stage of cancerous cells invading other organs, then its rapid
detection would be very useful in the clinical setting for early screening and treatment.
From previous studies involving the development of CT26-FL3 cells, a highly metastatic
cell line, the gene encoding the protein Lcn2 was found to be greatly expressed in the
metastatic liver both against other genes and the transcriptional genome of the sham
control group of mice that were not injected with CT26-FL3 cells.
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To begin studying the effect of overexpressing LCN2 on colon cancer metastasis
within the living mouse model, the plasmid pV1J-Lcn2 was constructed, purified, and
purified under large-scale endotoxin-free conditions to prepare for in vivo
electroporation. This method was chosen to be able to continuously express Lcn2 in the
bloodstream over extended periods of time via entry by a stable plasmid. Mice were
chosen to be in the following treatment groups: 50 μg of pV1J empty vector, and 50 μg of
pV1J-Lcn2. These dosages were injected into the quadriceps muscle of the mice and
incorporated into the blood stream by in vivo electroporation at 100V for 50 milliseconds.
Blood was taken from the retro-orbital eye sinus 1 day before and once a week after
electroporation for further analysis of LCN2 levels in the blood sera. Averaged samples
for each group measured from ELISA determined increasing circulation of Lcn2 in the
blood stream for the experimental group injected with pV1J-Lcn2, while for the other
controls group pV1J empty vector expression decreased after 1 week.
The findings from in vivo electroporation seems to be a viable method for the
stable and continuous expression of LCN2. Mice injected with the pV1J-Lcn2 plasmid
show an increase in the Lcn2 gene in blood sera over the 4 week study. The initial prebleed concentrations (before plasmid injection and cell implantation) were similar. After
the injection of the gene there is nearly a 2 fold change in the concentration in the sera
after weekly electroporation. The pV1J-Lcn2 and pV1J empty vector mice concentrations
returned to similar levels when mice were not electroporated with stable plasmids (pV1JLcn2 and pV1J empty vector), suggesting that LCN2 may have a role in colorectal
metastasis. A western blot was also conducted to analyze the blood sera in mice with
pV1J empty vector and pV1J- Lcn2 and the findings show an increase in the Lcn2 gene
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over the course of the study.
The increased levels of LCN2 showed a positive correlation in metastasis. There
was significance between the livers of pV1J- Lcn2 and pV1J empty vector mice. The rate
of metastasis was much higher and level of metastasis was higher on the appearance of
the actual liver suggesting that something is happening in the tumor microenvironment
with the gene Lcn2. What exactly is happening is a question that needs to examine more
thoroughly and will take more experiments to answer this questions. Conversely, the
spleen (primary tumor) of pV1J- Lcn2 and pV1J empty vector, there was no significance
difference between the two groups.
Future experiments can continue directly from these conclusions, the
identification of Bone Marrow Derived Cells found in the hepatic microenvironment
throughout tumor progression in our orthotopic mouse model. Also, determine if
increased LCN2 is positively correlated with metastasis and carcinogenesis in our mouse
model through invasion assays. Analogous studies can be performed with Lcn2 inhibition
whether it is by Lcn2 gene knock out, silencing Lcn2 by siRNAs, or other similar
methods to study the influence of absence of LCN2 in colon cancer metastasis to the
liver.
If these results follow in line with current findings, rates of metastasis should
decrease without stimulus from Lcn2. Since LCN2 limits bacterial growth by
sequestering iron carrying siderophores, it may alter cancerous cell proliferation by
affecting iron in some way, though this is entirely speculation at this point. Overall, these
are merely the beginning investigations on the role of LCN2, though they show some
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promise in its possible crucial involvement for the progression of colon cancer metastasis
to the liver. Additional studies must be undertaken to further elucidate LCN2 exact
molecular interactions within the tumor microenvironment and beyond.
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